ProCE Banner Activity

T-Cell Lymphomas: Where We Are and Where We Are Going

Clinical Thought
Get an overview of where we are now and where we are headed in the management of patients with T-cell lymphomas in this expert commentary.

Released: November 08, 2022

Expiration: November 07, 2023

No longer available for credit.

Share

Faculty

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo

Kyowa Kirin Inc

Seagen Inc.

Faculty Disclosure

Primary Author

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD: consultant/advisor/speaker: Acrotech, C4 Therapeutics, Cimeio Therapeutics, Myeloid Therapeutics, Seattle Genetics, Shoreline Biosciences, Takeda, Tubulis, Vividion Therapeutics.